Drugs /

nab-paclitaxel

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

NCI Definition [1]:
A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for nab-paclitaxel

Nab-paclitaxel has been investigated in 137 clinical trials, of which 115 are open and 22 are closed. Of the trials investigating nab-paclitaxel, 2 are early phase 1 (2 open), 38 are phase 1 (29 open), 29 are phase 1/phase 2 (24 open), 49 are phase 2 (43 open), 1 is phase 2/phase 3 (1 open), 16 are phase 3 (14 open), and 2 are no phase specified (2 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for nab-paclitaxel clinical trials.

Breast carcinoma, pancreatic adenocarcinoma, and pancreatic ductal adenocarcinoma are the most common diseases being investigated in nab-paclitaxel clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Nab-Paclitaxel
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Nab-Paclitaxel
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating nab-paclitaxel and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
paclitaxel protein-bound, abi007, albumin-bound paclitaxel, nanoparticle paclitaxel, nanoparticle albumin-bound paclitaxel, abi 007, albumin-stabilized nanoparticle paclitaxel, albumin-bound paclitaxel, nanoparticle paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, abi-007, nab paclitaxel, 130-nm albumin-bound paclitaxel, protein-bound paclitaxel, protein-bound paclitaxel, nanoparticle albumin-bound paclitaxel, abraxane
NCIT ID [1]:
C2688
SNOMED ID [1]:
F-62186

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.